Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Steve_Harr
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
regenerative medicine
gene therapy cell engineering |
| gptkbp:foundedIn |
2018
|
| gptkbp:founder |
gptkb:Hans_Bishop
gptkb:Richard_Klausner gptkb:Steve_Harr |
| gptkbp:headquartersLocation |
gptkb:Seattle,_Washington,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sana Biotechnology
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:IPODate |
2021
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:mission |
develop engineered cells as medicines for patients
|
| gptkbp:notableInvestment |
gptkb:F-Prime_Capital
gptkb:Flagship_Pioneering gptkb:ARCH_Venture_Partners GV (formerly Google Ventures) |
| gptkbp:numberOfEmployees |
approximately 350 (2023)
|
| gptkbp:researchArea |
ex vivo cell engineering
in vivo cell engineering |
| gptkbp:stockSymbol |
gptkb:SANA
|
| gptkbp:website |
https://sana.com/
|
| gptkbp:bfsParent |
gptkb:Sangeeta_Bhatia
|
| gptkbp:bfsLayer |
4
|